BestimБестим
A synthetic dipeptide with a gamma peptide bond between D-glutamate and L-tryptophan (γ-D-Glu–L-Trp). Studies examined immune-cell binding and its use alongside standard treatment.
What the studies found
Observational study · 2018
[Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia].
- Affective-asthenic subgroup
- 32.5%
- Asthenic-negative subgroup
- 67.5%
- Later symptom regression in asthenic-negative subgroup
- More marked in the authors’ comparisonp<0.001
Adjunctive Bestim was associated with reduced asthenic symptom scores during complex psychiatric treatment.
Study notes · methods, sources and limitations
Participants or model 43 men aged 20–55 with schizophrenia and asthenic symptoms
Design 43 men aged 20–55 with schizophrenia and asthenia; clinical assessments before treatment and 5/30 days afterward.
Important limitations
- An untreated concurrent control and random allocation are not established by the abstract; improvement cannot be attributed to Bestim alone. Full methods, reporting completeness and independent replication remain to be appraised.
- The percentages describe symptom categories, not responder rates.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 29652309 · Original journal report
Observational study · 2004
[Impact of Bestim on the immunological status and clinical course of ulcer].
The report describes immune-marker changes, symptom regression and ulcer scarring with adjunctive Bestim.
Study notes · methods, sources and limitations
Participants or model Patients receiving combined antiulcer treatment; sample size absent from abstract
Important limitations
- Sample size, comparator details and quantitative effects require the full report; this is not reliable evidence of standalone efficacy. Full methods, reporting completeness and independent replication remain to be appraised.
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 16259438 · Original journal report
Lab research · 2008
Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes
Study of multiple preparations
- Bestim binding Kd, intact macrophages/thymocytes
- 2.1 ± 0.1 / 3.1 ± 0.2 nM
- Bestim binding Kd, isolated membranes
- 18.6 ± 0.2 / 16.7 ± 0.3 nM
- Thymogen competition Ki
- 0.9 ± 0.1 / 1.1 ± 0.1 nM
Radiolabeled gamma-D-Glu-L-Trp bound mouse immune cells; unlabeled Thymogen competed for binding. This supports a shared binding interaction under assay conditions, not equivalent immunological outcomes in people.
More reported outcomes
- Bestim adenylate-cyclase inhibition range
- 10⁻¹⁰–10⁻⁶ M
Study notes · methods, sources and limitations
Participants or model Murine macrophages, thymocytes and isolated membranes
Design Radiolabeled Bestim binding to mouse macrophages/thymocytes and isolated membranes; tracer activity 45 Ci/mmol.
Important limitations
- Cell-binding experiment, not a clinical trial. Preserve gamma linkage and D/L stereochemistry; generic database synonyms may be misleading.
- Binding affinities are not clinical dose equivalences. The Ki row concerns Thymogen competition, not Bestim Kd.
Primary source linked above · Indexed abstract
About Bestim
Names in this research collection
gamma-D-Glu-L-Trp · γ-D-Glu-L-Trp
Research background
A gamma-linked D-Glu/L-Trp dipeptide with immune-cell binding research and limited human adjunct-treatment reports. Distinct from Thymogen and Thymodepressin.
Autoimmune research: disease-specific findings, immune effects and open questions ↗
- Compound class
- Peptide research family
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
43 men aged 20–55 with schizophrenia and asthenic symptoms
Study methods
Study records describe the tested models, comparators and reported outcomes.
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
New indexed primary abstracts and/or report reproductions linked; review depth shown per source
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Patents and claimed inventions
These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2018
Gamma-D-Glu-L-Trp: interferon combination claim — RU2672861C2
Clinical examples describe symptom resolution during treatment, without a controlled patient efficacy estimate.
Pharyngitis example · Initial improvement followed by worsening the next day; no complaints by day 5 · One 27-year-old patient; the transient worsening is retained
Study notes and original source
Gamma-D-Glu-L-Trp: interferon combination claim — RU2672861C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Евгения Валерьевна Безрукова, Илья Владимирович Духовлинов, Александр Митрофанович Ищенко, Александр Леонидович Кадыков, Александр Александрович Колобов, Александр Владимирович Петров, Андрей Семенович Симбирцев · RU2672861C2 · patent family 56095723
Clinical examples describe symptom resolution during treatment, without a controlled patient efficacy estimate.
Results and tables
Reported patent results
Findings described in words
Clinical examples describe symptom resolution during treatment, without a controlled patient efficacy estimate.
Selected clinical examples of gamma-D-Glu-L-Trp plus interferon; the observations concern a combination, not standalone Bestim.
Population or model Selected clinical examples of gamma-D-Glu-L-Trp plus interferon; the observations concern a combination, not standalone Bestim.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pharyngitis example | Initial improvement followed by worsening the next day; no complaints by day 5 | One 27-year-old patient; the transient worsening is retained |
| Respiratory-illness example | Nasal discharge reportedly stopped and general condition improved by day 3 | Individual case; natural recovery and concurrent effects are not separated |
Uncontrolled short-duration cases do not establish superiority to either component. The D/L molecule must remain distinct from the older L/L Bestim patent.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Selected clinical examples of gamma-D-Glu-L-Trp plus interferon; the observations concern a combination, not standalone Bestim.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- This is a combination claim rather than a patent on standalone Bestim efficacy; it does not resolve the older L/L-versus-D/L naming conflict.
- Uncontrolled short-duration cases do not establish superiority to either component. The D/L molecule must remain distinct from the older L/L Bestim patent.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Experiment described in a patent · 1998
Bestim: historical stereochemistry conflict — RU2120298C1
The patent reports restoration of lymphocyte measures in a selected case, with no controlled clinical effect estimate.
Study notes and original source
Bestim: historical stereochemistry conflict — RU2120298C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
О.А. Кауров, С.А. Кетлинский, А.А. Колобов, А.С. Симбирцев · RU2120298C1 · patent family 20174019
The patent reports restoration of lymphocyte measures in a selected case, with no controlled clinical effect estimate.
Results and tables
Reported patent results
Findings described in words
The patent reports restoration of lymphocyte measures in a selected case, with no controlled clinical effect estimate.
Historical Bestim patent describes gamma-L-Glu-L-Trp and selected immunodeficiency cases, including a patient after thymus removal.
Population or model Historical Bestim patent describes gamma-L-Glu-L-Trp and selected immunodeficiency cases, including a patient after thymus removal.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Post-thymectomy case | Total and T-lymphocyte measures described as returning to normal; patient discharged in satisfactory condition | Single 18-year-old patient; image-based numerical table not transcribed |
| Other selected case | Colon-cancer-associated immunodeficiency example described | No verified group response rate or independently extracted effect size |
This L/L patent molecule differs from the D/L sequence on the current Bestim research card. Name similarity cannot transfer the clinical observation to a different stereoisomer.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Historical Bestim patent describes gamma-L-Glu-L-Trp and selected immunodeficiency cases, including a patient after thymus removal.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- These stereoisomers cannot be treated as identical. The name alone does not establish continuity between the patent, later literature and current products.
- This L/L patent molecule differs from the D/L sequence on the current Bestim research card. Name similarity cannot transfer the clinical observation to a different stereoisomer.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Observational study · 2018
[Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia].
Adjunctive Bestim was associated with reduced asthenic symptom scores during complex psychiatric treatment.
Affective-asthenic subgroup · 32.5%
Study notes and original source
[Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia].
· Original journal report
Yakimets AV, Zozulya SA, Oleichik IV, Klyushnik TP · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · PMID 29652309
Adjunctive Bestim was associated with reduced asthenic symptom scores during complex psychiatric treatment.
Results and tables
Reported findings and study design
43 men aged 20–55 with schizophrenia and asthenia; clinical assessments before treatment and 5/30 days afterward.
Population or model 43 men aged 20–55 with schizophrenia and asthenic symptoms
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Affective-asthenic subgroup | 32.5% | |
| Asthenic-negative subgroup | 67.5% | |
| Later symptom regression in asthenic-negative subgroup | More marked in the authors’ comparison | p<0.001 |
The percentages describe symptom categories, not responder rates.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 43 men aged 20–55 with schizophrenia and asthenic symptoms
- Source reviewed
- Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
- An untreated concurrent control and random allocation are not established by the abstract; improvement cannot be attributed to Bestim alone.
- Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-10-05.
Observational study · 2004
[Impact of Bestim on the immunological status and clinical course of ulcer].
The report describes immune-marker changes, symptom regression and ulcer scarring with adjunctive Bestim.
Study notes and original source
[Impact of Bestim on the immunological status and clinical course of ulcer].
· Original journal report
Tkacheva AG, Kalev OF, Dolgushina AI, Antipina TV · Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · PMID 16259438
The report describes immune-marker changes, symptom regression and ulcer scarring with adjunctive Bestim.
- Population / setting
- Patients receiving combined antiulcer treatment; sample size absent from abstract
- Source reviewed
- Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Study limitations
- Sample size, comparator details and quantitative effects require the full report; this is not reliable evidence of standalone efficacy.
- Full methods, reporting completeness and independent replication remain to be appraised.
Reviewed 2026-10-05.
Lab research · 2008
Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes
Radiolabeled gamma-D-Glu-L-Trp bound mouse immune cells; unlabeled Thymogen competed for binding. This supports a shared binding interaction under assay conditions, not equivalent immunological outcomes in people.
Study notes and original source
Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes
· Primary source linked above
Radiolabeled gamma-D-Glu-L-Trp bound mouse immune cells; unlabeled Thymogen competed for binding. This supports a shared binding interaction under assay conditions, not equivalent immunological outcomes in people.
Results and tables
Reported findings and study design
Radiolabeled Bestim binding to mouse macrophages/thymocytes and isolated membranes; tracer activity 45 Ci/mmol.
Population or model Murine macrophages, thymocytes and isolated membranes
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Bestim binding Kd, intact macrophages/thymocytes | 2.1 ± 0.1 / 3.1 ± 0.2 nM | |
| Bestim binding Kd, isolated membranes | 18.6 ± 0.2 / 16.7 ± 0.3 nM | |
| Thymogen competition Ki | 0.9 ± 0.1 / 1.1 ± 0.1 nM | |
| Bestim adenylate-cyclase inhibition range | 10⁻¹⁰–10⁻⁶ M |
Binding affinities are not clinical dose equivalences. The Ki row concerns Thymogen competition, not Bestim Kd.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Murine macrophages, thymocytes and isolated membranes
- Source reviewed
- Selected original-source text checked; full methodological review pending.
Study limitations
- Cell-binding experiment, not a clinical trial.
- Preserve gamma linkage and D/L stereochemistry; generic database synonyms may be misleading.
Reviewed 2026-10-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗